Abstract: Objective To observe the efficacy and safety of gemcitabine combined with capecitabine or fluorouracil（5-FU）， cisplatin or carboplatin and hydroxycamptothecine（HCPT） rescue treatment after failure of taxane and anthracycline therapy in patients with metastatic breast cancer， providing reference for the eligible chemotherapy for metastatic breast cancer that has progressed after axane and anthracycline therapy. Methods Sixty-five patients progressive to taxane and anthracycline therapy were enrolled. Subgroup and chemotherapy regimen were： GX group： gemcitabine 800-1000mg／m2， d1， d8， capecitabine 850-1000mg／m2 bid， d1-14 or 5-FU 500mg／m2 d1-5； GP group： gemcitabine 800-1000 mg／m2， d1， d8， cisplatin 70mg／m2 or carboplatin AUC=46； GH group： gemcitabine 800-1000 mg／m2， d1， d8， HCPT 6-8 mg／d， sharing 5-6 days. Three weeks was a cycle. The efficacy was evaluated every 2 cycles. The patients with disease control were given six cycles of chemotherapy. Results Sixty-four patients were available for objective response evaluation， and adverse events were evaluated among 65 patients. The response rates were 36.4％， 33.3％ and 30.0％ in GX-group， GP-group and GH-group， respectively（P＞0.05）. The median progression free survival were 8（1-22）months， 8（1-48）months and 6（2-12）months without significant difference（P=0.415）；the median overall survival were 14.5（6-37） months， 14（4-48）months and 16（5-63）months without significant difference（P=0.653）. The incidence rates of grade 34 adverse reactions were low among 3 groups. Conclusion The treatment of gemcitabine-based combined chemotherapy regimen showed good efficacy in metastatic breast cancer patients with failure of taxane and anthracycline therapy.